ReWalk Robotics highlighted two recent research publications that demonstrate the effectiveness of the unique propulsion training capabilities of the ReStore Exo-Suit for post-stroke rehabilitation. The most recent publication, from the University of Pecs in Hungary, titled “Investigation of the Effectiveness of the Robotic ReStore Soft Exoskeleton in the Development of Early Mobilization, Walking, and Coordination of Stroke Patients: A Randomized Clinical Trial” examined key walking metrics for two groups of post-stroke patients, randomized to either a conventional therapy program or a program which included training with the ReStore Exo-Suit. The ReStore intervention group demonstrated significant improvements compared to the control group, including a 56% increase in 10-meter walking speed, and a 68% improvement in 6-minute walking distance, and the improved performance was demonstrated to persist at the post-intervention follow up assessment. A second study from Boston University was presented in an abstract titled “Durable Improvements in Post-Stroke Walking Speed and Distance Following High-Intensity Training with Soft Robotic Exosuits.” This study demonstrated that a 4-week program of intensive gait training with the ReStore Exo-Suit for individuals post-stroke resulted in clinically meaningful increases in walking speed and walking distance which endured a month after the individual had completed the training program. These improvements in speed and distance were accompanied by significant improvements in propulsion mechanics of the paretic limb.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LFWD:
- Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered
- Lifeward says CMS defers final decision on pricing for personal exoskeletons
- Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results
- Lifeward sees Q1 revenue $5M-$5.5M
- Lifeward sees 2024 revenue $28M-$32M